About this trial
A total of 120 obese gout patients were included in a 24-week double-blind randomized controlled design. The intervention group received orlistat 120 mg tid + UTL + individualized diet-exercise-behavioral reinforcement weight loss program, while the control group received a placebo + UTL + standard recommendations. The primary endpoint was the rate of achieving serum uric acid levels \<360 μmol/L at 24 weeks; secondary endpoints included the proportion of weight loss ≥5%, frequency of gout attacks, and inflammatory indicators such as CRP and IL-1β; the activity of AMPK in PBMCs and the expression of HIF1α and NLRP3 inflammasome-related proteins were also assessed.
Eligibility criteria
Qualifiers
Meeting the 2015 ACR/EULAR classification criteria for gout.
Age 18-70 years.
BMI ≥28 kg/m².
Serum uric acid ≥480 μmol/L.
Disqualifiers
Contraindications to orlistat or other gout medications.
Severe hepatic or renal dysfunction.
History of severe allergy or adverse reactions to study drugs.
Pregnant or lactating women.
Trial design
Treatments tested in this trial
- Orlistat 120 mg
- Allopurinol 100 up to 600mg/day
- Febuxostat 40mg Tab
Treatment groups
Sponsors and collaborators
XueMei Guo
Lead sponsor
General Hospital of Shenyang Military Region
Sponsor institution
Shengjing Hospital
Collaborator
The People's Hospital of Liaoning Province
Collaborator